In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes program. This program took a multifaceted approach to providing key funding to diabetes researchers to advance a broad spectrum of research programs on all aspects of understanding, managing, and treating diabetes. Here, the personal perspective of a 2019 Pathway Accelerator awardee is offered, describing a research program seeking to advance a materials-centered approach to engineering glucose-responsive devices and new delivery tools for better therapeutic outcomes in treating diabetes. This is offered alongside a personal reflection on 5 years of support from the ADA Pathway Program.

Article Highlights
  • Five years of support from the ADA Pathway to Stop Diabetes program has resulted in significant progress from a research program on glucose-responsive therapeutics.

  • New chemistry for more sensitive and specific glucose binding has enabled improvements in materials and formulations for insulin delivery.

  • A new approach to glucose-stabilized materials has enabled materials and formulations for the delivery of glucagon.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at
You do not currently have access to this content.